Uncaria tomentosa—Adjuvant Treatment for Breast Cancer: Clinical Trial

Table 3

Immune status of breast cancer patients before treatment and after 6 cycles of chemotherapy without Uncaria tomentosa supply (Ca group) or receiving 300 mg/day of Uncaria tomentosa (UtCa group).

Parameters	Group	Chemotherapy cycles
		0	6
CD4^+ T cells	UtCa	1008.25 (379.21)	786.60 (310.49)
Cells/μL	Ca	1053.00 (620.81)	798.00 (366.14)
CD8^+ T cells	Ut Ca	568.81 (295.60)	459.87 (246.46)
Cells/μL	Ca	679.84 (273.22)	565.62 (231.05)
CD4^+T/CD8^+T ratio	UtCa	2.044 (0.62)	1.858 (0.89)
	Ca	1.630 (0.69)	1.652 (0.49)
IL6	UtCa	3.4 (4.50)	2.1 (6.6)
pg/mL	Ca	5.6 (5.53)	3.8 (7.312)

Data expressed as mean ± standard deviation; UtCa group: patients treated with chemotherapy +300 mg Uncaria tomentosa daily (𝑛=20); Ca group: patients received chemotherapy (𝑛=20).